Table 1

Characteristic of included studies

First author, yearStudy identifierCountriesStudy designFollow-up (weeks)Basal insulinPatients (n)Inclusion criteria
Davies, 200517AT.LANTUS59 countries in Western and Eastern Europe, South America, Asia, and Africa/Middle EastRCT24Glargine U-1005033T2D, ≥18 years, HbA1c 7.0%–12.0% (53–108 mmol/mol), BMI <40 kg/m2, on oral therapy with or without insulin.
Meneghini, 200718PREDICTIVE 303USARCT26Detemir5619T2D, ≥18 years, HbA1c ≤12.0% (108 mmol/mol), BMI ≤45 kg/m2, newly diagnosed or on oral therapy with or without basal insulin.
Garg, 2015 19ATLASChina, India, Japan, Pakistan, Russia, and the PhilippinesRCT24Glargine U-100555T2D, 40–75 years, HbA1c 7.0%–11.0% (53–97 mmol/mol), BMI 20–40 kg/m2, insulin-naive.
Yale, 2017 20TITRATIONCanadaRCT12Glargine U-300212T2D, ≥18 years, HbA1c 7.0%–11.0% (53–97 mmol/mol), insulin-naive or on basal insulin with or without non-insulin antihyperglycemic therapy.
Russell-Jones, 201921Take ControlCroatia, Czech Republic, Denmark, Greece, Poland, Slovakia, Slovenia, Spain, Switzerland, UKRCT24Glargine U-300631T2D, ≥18 years, HbA1c 7.0%–11.0% (53–97 mmol/mol), on at least one non-insulin antihyperglycemic therapy with or without basal insulin.
Bonadonna, 202022ITASItalyRCT24Glargine U-300359T2D, ≥18 years, HbA1c 7.5%–10.0% (58–86 mmol/mol), insulin-naive.
  • BMI, body mass index; HbA1c, hemoglobin A1c; RCT, randomized controlled trial; T2D, type 2 diabetes.